Drug Safety Changes Should Await IoM, HHS Secretary Tells Congress
Executive Summary
HHS Secretary Michael Leavitt is urging Congress to be patient in considering potential changes to FDA's regulation of drug safety
You may also be interested in...
IoM’s Drug Safety Cmte. Will Meet In June; Panel Includes Ex-FDAer Ellenberg
The Institute of Medicine's Drug Safety Committee will convene June 8 to begin discussing its review of FDA's post-marketing oversight system
IoM’s Drug Safety Cmte. Will Meet In June; Panel Includes Ex-FDAer Ellenberg
The Institute of Medicine's Drug Safety Committee will convene June 8 to begin discussing its review of FDA's post-marketing oversight system
Office Of New Drugs Oversight Of Advisory Committees Creates Bias – Graham
The Office of New Drugs' authority over FDA advisory committees creates a bias in industry's favor, Office of Drug Safety Associate Director for Science David Graham said March 21 during a National Press Club "Newsmakers" conference in Washington, D.C